COMPARISON OF GLECAPREVIR/PIBRENTASVIR AND SOFOSBUVIR/LEDIPASVIR AS PANGENOTYPIC DAA IN PATIENTS WITH CHRONIC HEPATITIS C IN SOUTH KOREA: MULTICENTER STUDY

被引：0
|
作者：
Kim, SukBae [1 ,2 ]
Song, Han, II [3 ]
Lee, Sae Hwan [4 ,5 ]
Kim, Hong Soo, II [5 ]
Lee, Tae Hee [6 ,7 ]
Soo, Eun Hyuk [8 ]
Kim, Seok Hyun [9 ]
Lee, Byung Seok [10 ]
Chae, Hee Bok [11 ]
Song, Myeong Jun [12 ]
Ko, Soon Young [13 ]
机构：
[1] Dankook Univ Coll Med, Yongin, South Korea
[2] Dankook Univ Hosp, Dankook Univ Coll Med, Dept Internal Med, Cheonan, South Korea
[3] Dankook Univ Hosp, Cheonan, South Korea
[4] Soonchunhyang Univ, Asan, South Korea
[5] Soonchunhyang Univ Cheonan Hosp, Gastroenterol, Cheonan, South Korea
[6] Konyang Univ Coll Med, Dept Internal Med, Nonsan, South Korea
[7] Konyang Univ Hosp, Daejeon, South Korea
[8] Chungnam Natl Univ, Sch Med, Dept Internal Med, Munhwa Ro, 282 Munhwa-Ro, Daejeon 35015, South Korea
[9] Chungnam Natl Univ Hosp, Dept Gastroenterol, 282 Munhwa-Ro, Daejeon 35015, South Korea
[10] Chungnam Natl Univ Hosp, Dept Gastroenterol, Daejeon, South Korea
[11] Chungbuk Natl Univ Hosp, Chungbuk Natl Univ Coll Med, Dept Internal Med, Cheongju, South Korea
[12] Catholic Univ Coll Med, Seoul, South Korea
[13] Konkuk Univ Coll Med, Seoul, South Korea
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1295
引用
收藏
页码：S386 / S386
页数：1
相关论文
共 50 条
  • [1] Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
    Shin, Hyun Deok
    Song, Il Han
    Lee, Sae Hwan
    Kim, Hong Soo
    Lee, Tae Hee
    Eun, Hyuk Soo
    Kim, Seok Hyun
    Lee, Byung Seok
    Chae, Hee Bok
    Kim, Seok Hwan
    Song, Myung Joon
    Ko, Soon Yeong
    Kim, Suk Bae
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (03): : 111 - 118
  • [2] Prospective multicenter study of glecaprevir plus pibrentasvir combination therapy for patients with chronic hepatitis C
    Tamori, Akihiro
    Iwasa, Motoo
    Inoue, Kazuaki
    Kagawa, Tatehiro
    Takaguchi, Koichi
    Minami, Masahito
    Iwasaki, Yoshiaki
    Nouso, Kazuhiro
    Hoang, Hai
    Enomoto, Masaru
    Kawada, Norifumi
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E242 - E243
  • [3] Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan
    Chiu, Wen-Nan
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Chen, Mei-Yen
    Tung, Shui-Yi
    Wei, Kuo-Liang
    Lu, Chung-Kuang
    Chen, Chien-Hung
    Hu, Tsung-Hui
    Hu, Jin-Hung
    Chen, Wei-Ming
    Chang, Te-Sheng
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) : 866 - 872
  • [4] Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children
    Pokorska-Sprimepiewak, Maria
    Talarek, Ewa
    Dobrzeniecka, Anna
    Aniszewska, Malgorzata
    Pluta, Magdalena
    Marczynska, Magdalena
    JOURNAL OF HEPATOLOGY, 2024, 80 : S820 - S821
  • [5] Comparison of effectiveness and safety between glecaprevir/pibrentasvir and sofosbuvir/velpatasvir in patients with chronic hepatitis C - A multi-institutional cohort study in Taiwan
    Hou, Mu-Hsuan
    Shao, Shih-Chieh
    Chen, Hui-Yu
    Chan, Yuk-Ying
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 126 - 126
  • [6] Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
    Pearlman, Brian
    Perrys, Michael
    Hinds, Andrew
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (09): : 1550 - 1552
  • [7] Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C: Results from a Spanish Cohort (Hepa-C)
    Puigvehi, Marc
    Albillos, Agustin
    Viu, Ana
    Hernandez Guerra, Manuel Nicolas
    Fernandez, Inmaculada
    Prieto, Martin
    Torras Collell, Xavier
    Rosales Zabal, Jose Miguel
    Grande, Lourdes
    Morillas, Rosa
    Diago, Moises
    De Cuenca, Beatriz
    Delgado, Manuel
    Bonet, Lucia
    Turnes, Juan
    Crespo, Javier
    Baliellas, Carme
    Luis Calleja, Jose
    Badia, Ester
    Manuel Pascasio, Juan
    Moreno Planas, Jose Maria
    Bernal, Vanesa
    Carmona, Isabel
    Fernandez, Miguel
    Salmeron, Javier
    Bellot, Pablo
    Gonzalez-Santiago, Jesus M.
    Luisa Gutierrez, Maria
    Javier Moreno, J.
    Anton, Maria Dolores
    De La Vega, Juan
    Escudero-Garcia, Desamparados
    Arenas, Juan
    Antonio Carrion, Jose
    HEPATOLOGY, 2018, 68 : 357A - 358A
  • [8] Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic Hepatitis C aged 75 years or older: A multicenter study
    Pugliese, N.
    Calvaruso, V.
    Masarone, M.
    D'Ambrosio, R.
    Battistella, S.
    Licata, A.
    Persico, M.
    Anolli, M. P.
    Distefano, M.
    Petta, S.
    Russo, F. P.
    Di Marco, V.
    Aghemo, A.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S26 - S26
  • [9] Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study
    Morita, Atsuhiro
    Tamaki, Nobuharu
    Kobashi, Haruhiko
    Mori, Nami
    Tsuji, Keiji
    Takaki, Shintaro
    Hasebe, Chitomi
    Akahane, Takehiro
    Ochi, Hironori
    Mashiba, Toshie
    Urawa, Naohito
    Fujii, Hideki
    Mitsuda, Akeri
    Kondo, Masahiko
    Ogawa, Chikara
    Uchida, Yasushi
    Narita, Ryoichi
    Marusawa, Hiroyuki
    Kubotsu, Yoshihito
    Matsushita, Tomomichi
    Shigeno, Masaya
    Yoshida, Hideo
    Tanaka, Katsuaki
    Okamoto, Eisuke
    Kasai, Toyotaka
    Ishii, Toru
    Okada, Kazuhiko
    Kurosaki, Masayuki
    Izumi, Namiki
    JGH OPEN, 2024, 8 (04):
  • [10] SOFOSBUVIR/VELPATASVIR VS GLECAPREVIR/PIBRENTASVIR IN GENOTYPE 3 HEPATITIS C VIRUS INFECTED PATIENTS
    Margusino-Framinan, L.
    Cid-Silva, P.
    Rotea-Salvo, S.
    Mena-de-Cea, A.
    Delgado, M.
    Vazquez-Rodriguez, P.
    Sanclaudio-Luhia, I
    Suarez-Lopez, F.
    Herranz, I
    Castro-Iglesias, A.
    VALUE IN HEALTH, 2019, 22 : S640 - S640
12345